Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor

Member of:

    ORCID: 0000-0003-2611-5642

    Publication year:
    All
    151 - 200 out of 236Page size: 50
    Sort by: 1st author
    1. Published

      Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice.

      Gunnarsson, P. T., Winzell, M. S., Deacon, Carolyn F., Larsen, M. O., Jelic, K., Carr, R. D. & Ahrén, B., 2006, In: Endocrinology. 147, 7, p. 3173-80 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    2. Published

      Sensory nerve desensitization by resiniferatoxin improves glucose tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and is associated with reduced plasma activity of dipeptidyl peptidase IV.

      Gram, D. X., Hansen, A. J., Deacon, Carolyn F., Brand, C. L., Ribel, U., Wilken, M., Carr, R. D., Svendsen, O. & Ahrén, B., 2005, In: European Journal of Pharmacology. 509, 2-3, p. 211-7 6 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Published

      Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test

      Gjesing, A. P., Kjems, L. L., Vestmar, M. A., Grarup, Niels, Linneberg, Allan René, Deacon, Carolyn F., Holst, Jens Juul, Pedersen, Oluf Borbye & Hansen, Torben, 1 Jan 2011, In: Diabetologia. 54, 1, p. 103-10 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes

      Foley, J. E., Ligueros-Saylan, M., He, Y. L., Holst, Jens Juul, Deacon, Carolyn F., Dunning, B. E., Leone-Jones, A., Yu, T. & Kelley, D. E., 2008, In: Hormone and Metabolic Research. 40, 10, p. 727-730 3 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

      Foley, J. E., Ligueros-Saylan, M., He, Y., Holst, Jens Juul, Deacon, Carolyn F., Dunning, B. E., Leone-Jones, A., Yu, T. & Kelley, D. E., Oct 2008, In: Hormone and Metabolic Research. Supplement. 40, 10, p. 727-30 4 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    6. Published

      Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men

      Eelderink, C., Noort, M. W. J., Sozer, N., Koehorst, M., Holst, Jens Juul, Deacon, Carolyn F., Rehfeld, Jens Frederik, Poutanen, K., Vonk, R. J., Oudhuis, L. & Priebe, M. G., 2017, In: European Journal of Nutrition. 56, 3, p. 1063-1076 14 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    7. Published

      The structure of wheat bread influences the postprandial metabolic response in healthy men

      Eelderink, C., Noort, M. W. J., Sozer, N., Koehorst, M., Holst, Jens Juul, Deacon, Carolyn F., Rehfeld, Jens Frederik, Poutanen, K., Vonk, R. J., Oudhuis, L. & Priebe, M. G., Oct 2015, In: Food & Function. 6, 10, p. 3236-48 13 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    8. Published

      Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review

      Deacon, Carolyn F., Jan 2011, In: Diabetes, Obesity and Metabolism. 13, 1, p. 7-18 12 p.

      Research output: Contribution to journal › Review › Research › peer-review

    9. Published

      Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors

      Deacon, Carolyn F., 2020, In: Peptides. 125, 7 p., 170196.

      Research output: Contribution to journal › Review › Research › peer-review

    10. Published

      Commentary: Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?

      Deacon, Carolyn F., 2012, In: Diabetes. 61, 9, p. 2219-2220

      Research output: Contribution to journal › Journal article › Research › peer-review

    11. Published

      Physiology of incretins in health and disease

      Deacon, Carolyn F. & Ahren, B., 2011, In: Review of Diabetic Studies. 8, 3, p. 293-306 14 p.

      Research output: Contribution to journal › Review › Research › peer-review

    12. Published

      DPP-4 inhibition – advances in our understanding of diabetes management

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: European Endocrinology. 4, p. 47-49

      Research output: Contribution to journal › Review › Research

    13. Published

      Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

      Deacon, Carolyn F., 2019, In: Frontiers in Endocrinology. 10, 14 p., 80.

      Research output: Contribution to journal › Review › Research › peer-review

    14. Published

      Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

      Deacon, Carolyn F. & Lebovitz, H., 2016, In: Diabetes, Obesity and Metabolism. 18, 4, p. 333-347 15 p.

      Research output: Contribution to journal › Review › Research › peer-review

    15. Published

      A comparative review of DPP-4 inhibitors and sulphonylureas

      Deacon, Carolyn F. & Lebovitz, H., 2016, In: Diabetes, Obesity and Metabolism. 18, p. 333-347

      Research output: Contribution to journal › Journal article › Research › peer-review

    16. Published

      Potential cardiovascular effects of incretin-based therapies

      Deacon, Carolyn F. & Marx, N., 2012, In: Expert Review of Cardiovascular Therapy. 10, p. 337-351

      Research output: Contribution to journal › Review › Research › peer-review

    17. Published

      Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

      Deacon, Carolyn F., Mannucci, E. & Ahren, B., 2012, In: Diabetes, Obesity and Metabolism Online. 14, 8, p. 762-767

      Research output: Contribution to journal › Review › Research › peer-review

    18. Published

      Circulation and degradation of GIP and GLP-1

      Deacon, Carolyn F., 2004, In: Hormone and Metabolic Research. 36, p. 761-765

      Research output: Contribution to journal › Journal article › Research › peer-review

    19. Published

      Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-140 8 p.

      Research output: Contribution to journal › Review › Research › peer-review

    20. Published

      A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomised controlled trials

      Deacon, Carolyn F., 2018, In: Diabetes, Obesity and Metabolism. 20, Suppl. 1, p. 34-46

      Research output: Contribution to journal › Review › Research › peer-review

    21. Published

      Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

      Deacon, Carolyn F., 2020, In: Nature Reviews Endocrinology. 16, 11, p. 642-653

      Research output: Contribution to journal › Review › Research › peer-review

    22. Published

      What do we know about the secretion and degradation of incretin hormones?

      Deacon, Carolyn F., 2005, In: Regulatory Peptides. 128, 2, p. 117-24 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    23. Published

      Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

      Deacon, Carolyn F. & Holst, Jens Juul, Oct 2013, In: Expert Opinion on Pharmacotherapy. 14, 15, p. 2047-58 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    24. Published

      DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes

      Deacon, Carolyn F., Carr, R. D. & Holst, Jens Juul, 2008, In: Frontiers in Bioscience. 13, p. 1780-94 14 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    25. Published

      Differential regional metabolism of glucagon in anesthetized pigs.

      Deacon, Carolyn F., Kelstrup, M., Trebbien, R., Klarskov, L., Olesen, M. & Holst, Jens Juul, 2003, In: American Journal of Physiology: Endocrinology and Metabolism. 285, 3, p. E552-60

      Research output: Contribution to journal › Journal article › Research › peer-review

    26. Published

      Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

      Deacon, Carolyn F., Ahrén, B. & Holst, Jens Juul, 2004, In: Expert Opinion on Investigational Drugs. 13, 9, p. 1091-102 11 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    27. Published

      A review of dipeptidyl peptidase-4 inhibitors: Hot topics from randomized controlled trials

      Deacon, Carolyn F., Feb 2018, In: Diabetes, Obesity and Metabolism. 20, p. 34-46 13 p.

      Research output: Contribution to journal › Review › Research › peer-review

    28. Published

      Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.

      Deacon, Carolyn F. & Holst, Jens Juul, 2005, In: International Journal of Biochemistry & Cell Biology. 38, 5-6, p. 831-44 13 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    29. Published

      Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

      Deacon, Carolyn F., 2007, In: Diabetes, Obesity and Metabolism. 9 Suppl 1, p. 23-31 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    30. Published

      Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes

      Deacon, Carolyn F., Feb 2018, In: Peptides. 100, p. 150-157 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    31. Published

      Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Advances in Therapy. 26, 5, p. 488-99 11 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    32. Published

      GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.

      Deacon, Carolyn F., Plamboeck, A., Møller, Søren & Holst, Jens Juul, 2002, In: American Journal of Physiology: Endocrinology and Metabolism. 282, 4, p. E873-9

      Research output: Contribution to journal › Journal article › Research › peer-review

    33. Published

      Therapeutic strategies based on glucagon-like peptide 1.

      Deacon, Carolyn F., 2004, In: Diabetes. 53, 9, p. 2181-9 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    34. Published

      GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations.

      Deacon, Carolyn F., Plamboeck, A., Rosenkilde, Mette, de Heer, J. & Holst, Jens Juul, 2006, In: American Journal of Physiology: Endocrinology and Metabolism. 291, 3, p. E468-75

      Research output: Contribution to journal › Journal article › Research › peer-review

    35. Published

      Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

      Deacon, Carolyn F., 2008, In: Current Opinion in Investigational Drugs. 9, 4, p. 402-13 11 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    36. Published

      Potential of liraglutide in the treatment of patients with type 2 diabetes

      Deacon, Carolyn F., 2009, In: Vascular Health and Risk Management (Online). 5, 1, p. 199-211 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    37. Published

      Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.

      Deacon, Carolyn F. & Holst, Jens Juul, 2002, In: Biochemical and Biophysical Research Communications. 294, 1, p. 1-4 3 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    38. Published

      Immunoassays for the incretin hormones GIP and GLP-1

      Deacon, Carolyn F. & Holst, Jens Juul, 2009, In: Best Practice & Research: Clinical Endocrinology & Metabolism. 23, 4, p. 425-32 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    39. Published

      MK-431 (Merck).

      Deacon, Carolyn F., 2005, In: Current Opinion in Investigational Drugs. 6, 4, p. 419-26 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    40. Published

      Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

      Deacon, Carolyn F., 2007, In: Expert Opinion on Investigational Drugs. 16, 4, p. 533-45 12 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    41. Published

      Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

      Deacon, Carolyn F. & Holst, Jens Juul, Jan 2010, In: Expert Opinion on Investigational Drugs. 19, 1, p. 133-40 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    42. Published

      Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

      Deacon, Carolyn F., Nauck, M. A., Meier, J., Hücking, K. & Holst, Jens Juul, 2000, In: Journal of Clinical Endocrinology and Metabolism. 85, p. 3575-3581

      Research output: Contribution to journal › Journal article › Research › peer-review

    43. Published

      Human colon produces fully processed glucagon-like peptide-1 (7-36 amide).

      Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: FEBS Letters. 372, p. 269-272.

      Research output: Contribution to journal › Journal article › Research › peer-review

    44. Published

      Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo.

      Deacon, Carolyn F., Johnsen, A. H. & Holst, Jens Juul, 1995, In: Journal of Clinical Endocrinology and Metabolism. 80, p. 952-957

      Research output: Contribution to journal › Journal article › Research › peer-review

    45. Published

      Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

      Deacon, Carolyn F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O. & Holst, Jens Juul, 1998, In: Diabetologia. 41, p. 271-278

      Research output: Contribution to journal › Journal article › Research › peer-review

    46. Published

      Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects.

      Deacon, Carolyn F., Nauck, M. A., Nielsen, M. T., Pridal, L. & Holst, Jens Juul, 1995, In: Diabetes. 44, p. 1126-1131

      Research output: Contribution to journal › Journal article › Research › peer-review

    47. Published

      Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

      Deacon, Carolyn F., Danielsen, P., Klarskov, L., Holst, Jens Juul & Olesen, M., 2001, In: Diabetes. 50, p. 1588-1597

      Research output: Contribution to journal › Journal article › Research › peer-review

    48. Published

      Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

      Deacon, Carolyn F., Hughes, T. E. & Holst, Jens Juul, 1998, In: Diabetes. 47, p. 764-769

      Research output: Contribution to journal › Journal article › Research › peer-review

    49. Published

      Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes

      Deacon, Carolyn F., Holst, Jens Juul & Carr, R. D., 1999, In: Drugs of Today. 35, p. 159-170

      Research output: Contribution to journal › Journal article › Research › peer-review

    50. Published

      Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

      Deacon, Carolyn F., Wamberg, S., Bie, P., Hughes, T. E. & Holst, Jens Juul, Feb 2002, In: Journal of Endocrinology. 172, 2, p. 355-62 8 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    Previous 1 2 3 4 5 Next

    ID: 9220